Pfizer Inc.(PFE)

New York Stock Exchange
Sector: Healthcare | Industry: Drug Manufacturers - General
Pfizer Inc. logo

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Latest News & Analysis

Pfizer Stock Analysis: Lawsuit Resolution, Dividend, and Future Growth Potential | [PFE]
Apr 4, 2025

Pfizer (PFE): Navigating Legal Hurdles, Stock Volatility, and Future Growth

Pfizer (PFE) faces challenges but the GSK lawsuit resolution and cost-cutting offer upsides. High dividend yield may attract investors, but volatility and tariffs warrant caution.

Read more →
Pfizer (PFE) stock faces market pressures: ABRYSVO European expansion, tariff threats, and SCHD's exit analyzed for investors. Stay informed.
Apr 2, 2025

Pfizer (PFE): ABRYSVO Approval, Tariff Risks, and Dividend Dilemma

Pfizer Inc. (PFE) navigates EU approval of ABRYSVO, tariff threats, and dividend sustainability concerns amid ETF shifts. A deep dive into PFE's strategic response.

Read more →
Pfizer (PFE) Stock Analysis: Strategic Shift, Pipeline Focus, and Dividend Sustainability - A comprehensive investment analysis of Pfizer's growth outlook and potential.
Mar 26, 2025

Pfizer (PFE): Strategic Shift, Pipeline Focus, and Growth Outlook

Pfizer's strategic shift, pipeline focus, and dividend appeal analyzed. Learn how these factors shape its growth outlook and investment potential.

Read more →
Pfizer Stock Analysis: Examining PFE's Dividend, Strategic Shifts, and Investment Outlook
Mar 24, 2025

Pfizer (PFE): Strategic Shifts, Dividend Outlook, and Growth

Pfizer (PFE) navigates strategic shifts, a compelling dividend, and growth challenges. This analysis explores valuation, market sensitivity, and strategies to mitigate trade war risks.

Read more →
Pfizer's strategic shift: Haleon divestiture, China expansion, and dividend sustainability analysis.
Mar 19, 2025

Pfizer's Strategic Reset: Haleon Divestiture, China Expansion, and Dividend Outlook

Pfizer navigates strategic shifts: Haleon divestiture, China expansion, and dividend sustainability in a dynamic pharmaceutical landscape.

Read more →
Pfizer's growth strategy: Exploring sales tactics, Chinese market expansion, and Apretude's potential. Investment analysis included.
Mar 17, 2025

Pfizer (PFE): Sales, China, and Apretude Strategy Analysis

Pfizer (PFE) navigates post-pandemic market via sales revamp, China focus, Apretude. Financial analysis reveals fluctuating profitability. Valuation gap suggests undervaluation. Investors monitor catalysts.

Read more →
Pfizer's Oncology Breakthroughs: VERITAC-2 Trial Analysis, Financial Performance, and R&D Pipeline for Future Growth. Stay informed on strategic collaborations!
Mar 11, 2025

Pfizer (PFE): Oncology Breakthroughs, Financial Resilience, Dividend

Pfizer Inc. (PFE) navigates oncology breakthroughs, financial resilience, and dividend sustainability amidst challenges. Strategic collaborations and cost-cutting are crucial.

Read more →
Pfizer Stock Analysis: Intraday Performance, Financials, and Legal Challenges
Mar 5, 2025

Pfizer Inc.: Intraday Updates and Key Developments

Pfizer intraday update reveals robust revenue growth, dividend strength and legal challenges shaping its strategic trajectory.

Read more →
Pfizer's strategic shift: Oncology focus, regulatory expertise, and vaccine pipeline impact on PFE stock.
Feb 28, 2025

Pfizer's Strategic Shift: Oncology Focus & Vaccine Pipeline

Pfizer strategically focuses on oncology via collaborations like Summit Therapeutics, navigating regulatory changes and new coronavirus variants. Legal challenges and vaccine demand present risks.

Read more →
Pfizer's oncology strategy, regulatory changes, and market outlook, focusing on ADC collaborations and dividend sustainability. A financial analysis of PFE.
Feb 27, 2025

Pfizer: Oncology Strategy, Regulatory Changes, and Market Outlook

Pfizer focuses on oncology via collaborations, addresses coronavirus concerns, and faces a Depo-Provera probe. Cavazzoni's CMO role could streamline approvals, while value stocks gain traction.

Read more →
Pfizer's strategic shift: Oncology focus, regulatory expertise, and dividend opportunities. Latest news and analysis.
Feb 25, 2025

Pfizer's Strategic Shift: Oncology, Regulatory Expertise, and Dividend Prospects

Pfizer focuses on oncology with Ivonescimab, appoints Patrizia Cavazzoni as CMO, and navigates vaccine demand and legal challenges, maintaining investor appeal.

Read more →
Pfizer (PFE) stock analysis: insights on dividend yield, gene therapy, and market trends.
Feb 21, 2025

Pfizer's Strategic Shift: Pipeline Adjustments and Market Impact

A comprehensive, data-driven update on Pfizer Inc.'s strategic pivot, pipeline realignment, legal investigations, and market challenges.

Read more →
Pfizer's strategic shift: Gene therapy discontinuation, oncology focus, financial outlook, and legal challenges.
Feb 20, 2025

Pfizer's Strategic Pivot: Gene Therapy Setback and Oncology Focus

Pfizer navigates strategic shifts, ending gene therapy development while focusing on oncology amid legal scrutiny, impacting investor sentiment and future prospects.

Read more →
Doctor reviewing medical charts in a lab setting.
Feb 18, 2025

Pfizer: Navigating Oncology, Dividends, and Regulatory Challenges in 2025

A detailed data-driven update on Pfizer’s latest developments, clinical breakthroughs, and regulatory challenges affecting [PFE](/dashboard/companies/PFE).

Read more →
Pfizer logo in a pharmaceutical research lab.
Feb 18, 2025

Pfizer Faces Scrutiny Amidst Drug Developments & Headwinds

A comprehensive intraday analysis of Pfizer covering legal scrutiny, breakthrough clinical trials, dividend yields, and strategic market responses.

Read more →